Cowen analyst Ritu Baral raised the firm’s price target on Madrigal Pharmaceuticals to $309 from $129 and keeps an Outperform rating on the shares. The analyst said its data strongly supports US/EU approval for resmetirom in F2/F3 NASH and a $2B market opportunity. He notes the company is guiding to 1H2023 NDA submission.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDGL:
- Meet the Biotech Stock That Jumped Over 260% in One Day
- Madrigal Pharmaceuticals price target raised to $250 from $170 at Oppenheimer
- Madrigal Pharmaceuticals price target raised to $312 from $182 at JMP Securities
- Raymond James upgrades Madrigal to Market Perform after NASH data
- Madrigal Pharmaceuticals upgraded to Market Perform at Raymond James
